Dispiropyrrolidine Mdm2 Inhibitors for Restoring p53 Function
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current anti-tumor agents targeting the Mdm2-p53 interaction are limited, and there is a need for more effective compounds that inhibit Mdm2 activity to restore p53 function and suppress cancer cell growth.
Innovation Solution
Development of novel spiroprolinamide derivatives represented by general formula (1) that act as potent Mdm2 inhibitors, restoring p53 function by inhibiting Mdm2-p53 binding and ubiquitination, thereby inhibiting cancer cell proliferation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing Mdm2 inhibitors (spirooxindole, indole, pyrrolidine-2-carboxamide derivatives) are used, then Mdm2-p53 binding is inhibited, but the compounds have limited effectiveness and lack of novelty
Solution Approach 1:
The patent introduces a novel spiroprolinamide core structure with specific structural parameters (spiro linkage, prolinamide moiety, substituent patterns) that differentiate it from existing inhibitor classes. This structural parameter change creates a new chemical space while maintaining Mdm2 binding capability, thereby improving effectiveness and diversity simultaneously
Solution Approach 2:
The compound combines multiple functional elements into a composite structure: a spiro-linked framework integrating a prolinamide core with aromatic substituents (Ring A, Ring B, Ring C). This composite architecture synergistically enhances Mdm2 binding affinity and selectivity compared to single-structure inhibitors
2Reliability
If Mdm2 is overexpressed in cancer cells, then p53 function is suppressed and canceration is promoted, but existing inhibitors do not sufficiently restore p53 function
Solution Approach 1:
The spiroprolinamide compound acts preemptively by blocking the Mdm2-p53 interaction before Mdm2 can suppress p53 function. By occupying the Mdm2 binding site, it prevents the harmful ubiquitination and degradation of p53, thereby restoring p53's tumor-suppressive functions before cancer progression occurs
Solution Approach 2:
The compound serves as an intermediary molecule that disrupts the pathological Mdm2-p53 complex formation. It mediates the restoration of p53 stability and activity by competitively binding to Mdm2, thereby indirectly activating p53-dependent apoptosis and cell cycle arrest pathways in cancer cells
Data Source
AI summary
The present invention provides a dispiropyrrolidine derivative represented by the following formula (1), which has various substituents, inhibits interaction between Mdm2 protein and p53 protein and exhibits anti-tumor activity, wherein R1, R2, R3, ring A, and ring B in formula (1) respectively have the same meanings as defined in the specification.